Business Context and Reporting Period
This Form 8-K Current Report from Ocular Therapeutix, Inc. covers the Annual Meeting of Stockholders held on June 14, 2018. The company is incorporated in Delaware and is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes
No material financial changes are reported in this filing. The document details the outcomes of shareholder votes regarding board elections and auditor ratification.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future financial performance. It reports the following governance actions:
- Director Elections: Stockholders elected Antony Mattessich, W. James O'Shea, and Charles Warden as Class I directors to serve until the 2021 Annual Meeting.
- Auditor Ratification: Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
Important Facts for Investors to Verify
- Voting Results: Verify the specific vote counts for the three Class I director candidates, noting significant broker non-votes (14,553,989) for each.
- Auditor Support: Confirm the strong support for PricewaterhouseCoopers LLP, with 32,785,789 votes for and only 286,003 against.
- Emerging Growth Status: Note that the company has elected not to use the extended transition period for complying with new or revised financial accounting standards.